牛牛AI助理已提取核心訊息
On January 10, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing is intended to register additional shares for the company's 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan. Specifically, 2,287,751 additional shares of common stock are being registered for the Equity Incentive Plan, and 457,550 additional shares for the Employee Stock Purchase Plan. The company, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has incorporated by reference the contents of its previous Form S-8 filings from August 18, 2022, and February 16, 2023. The CEO and President, Timothy Lu, M.D., Ph.D., along with other executives and directors, have signed the registration statement, confirming the company's compliance with the requirements for filing on Form S-8.
On January 10, 2024, Senti Biosciences, Inc., a biotechnology company based in South San Francisco, California, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing is intended to register additional shares for the company's 2022 Equity Incentive Plan and 2022 Employee Stock Purchase Plan. Specifically, 2,287,751 additional shares of common stock are being registered for the Equity Incentive Plan, and 457,550 additional shares for the Employee Stock Purchase Plan. The company, which is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company, has incorporated by reference the contents of its previous Form S-8 filings from August 18, 2022, and February 16, 2023. The CEO and President, Timothy Lu, M.D., Ph.D., along with other executives and directors, have signed the registration statement, confirming the company's compliance with the requirements for filing on Form S-8.
2024年1月10日，總部位於加利福尼亞州南舊金山的生物技術公司Senti Biosciences, Inc. 向美國證券交易委員會提交了S-8表格的註冊聲明。該文件旨在爲公司的2022年股權激勵計劃和2022年員工股票購買計劃註冊更多股份。具體而言，股權激勵計劃額外註冊了2,287,751股普通股，員工股票購買計劃又註冊了457,550股普通股。該公司被歸類爲非加速申報人、小型申報公司和新興成長型公司，已以引用方式納入了其先前自2022年8月18日和2023年2月16日提交的S-8表格的內容。首席執行官兼總裁、醫學博士、博士生Timothy Lu以及其他高管和董事簽署了註冊聲明，確認公司遵守了提交S-8表格的要求。
2024年1月10日，總部位於加利福尼亞州南舊金山的生物技術公司Senti Biosciences, Inc. 向美國證券交易委員會提交了S-8表格的註冊聲明。該文件旨在爲公司的2022年股權激勵計劃和2022年員工股票購買計劃註冊更多股份。具體而言，股權激勵計劃額外註冊了2,287,751股普通股，員工股票購買計劃又註冊了457,550股普通股。該公司被歸類爲非加速申報人、小型申報公司和新興成長型公司，已以引用方式納入了其先前自2022年8月18日和2023年2月16日提交的S-8表格的內容。首席執行官兼總裁、醫學博士、博士生Timothy Lu以及其他高管和董事簽署了註冊聲明，確認公司遵守了提交S-8表格的要求。
有用
沒用